Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur Reports Results Of Clinical Trials Of Influenza A Vaccine
Sanofi Pasteur has reported the interim analysis of data from clinical trials of the US licensed Influenza A (H1N1) 2009 Monovalent Vaccine in infants and children 6 months
Sanofi Pasteur has reported the interim analysis of data from clinical trials of the US licensed Influenza A (H1N1) 2009 Monovalent Vaccine in infants and children 6 months
Ziopharm Oncology has reported positive top line interim data from the multicenter randomised phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue
Myriad Pharmaceuticals has identified an Investigational New Drug (IND) candidate targeting a novel molecular target, the protein kinase IKK epsilon. Reportedly, Myriad Pharmaceuticals’ IKK epsilon antagonist and IND
GlaxoSmithKline (GSK) and Prosensa, the Dutch-based biopharmaceutical company focusing on RNA modulating therapeutics, have entered into an exclusive worldwide collaboration for the development and commercialisation of RNA based
Novartis has entered into an agreement for exclusive US and Canadian rights to Fanapt(iloperidone), a new oral medication that is approved by the US Food and Drug Administration
Novavax has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Merck KGaA’s wholly-owned subsidiary in India, Merck Specialities, has acquired Bangalore Genei (BGIP) from the Sanmar Group. BGIP is located in Bangalore and specialises in the development, production,
The European Medicines Agency (EMA )has granted Orphan Drug Designation to Amsterdam Molecular Therapeutics’ (AMT) gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy. Reportedly, Orphan
SAFC Pharma has completed the addition to its Carlsbad, California facility that expands the company’s contract manufacturing services for its late phase and commercial clients. The $12m project
Antisoma has reported that its aptamer drug AS1411 has been granted orphan drug status in both the US and the EU for the treatment of acute myeloid leukaemia